Cover Image
市場調查報告書

成長/分化因素8 (肌肉生長抑制素/GDF-8):開發平台分析

Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 363561
出版日期 內容資訊 英文 67 Pages
訂單完成後即時交付
價格
Back to Top
成長/分化因素8 (肌肉生長抑制素/GDF-8):開發平台分析 Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Pipeline Review, H1 2016
出版日期: 2016年06月22日 內容資訊: 英文 67 Pages
簡介

本報告提供全球各國的增生/分化因素8 (肌肉生長抑制素或GDF-8) 治療藥的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊,為您概述為以下內容。

目錄

簡介

  • 分析範圍

成長/分化因素8 (肌肉生長抑制素/GDF-8)的概要

治療藥的開發情形

  • 臨床實驗的各階段
  • 各治療領域
  • 各症狀

開發中產品的概要

  • 後期階段的產品
  • 初期階段的產品

在各企業開發中的治療藥

治療藥的評估

  • 單劑治療藥/並用治療藥的情況
  • 各作用機制
  • 各投藥法
  • 各分子類型

開發治療藥的企業

  • Acceleron Pharma, Inc.
  • Atara Biotherapeutics, Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Milo Biotechnology LLC
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sarepta Therapeutics, Inc.
  • Scholar Rock, Inc.

藥物簡介

  • AAV1-forisutachin
    • 產品概要
    • 作用機制
    • 研究開發 (R&D)的發展情形
  • AAV9-forisutachin
  • ACE-083
  • ACE-2494
  • ACE-2798
  • DMD、貝克氏肌肉萎縮症 (MD) 的肌肉生長抑制素抑制用反義寡核苷酸
  • ATA-842
  • BMS-986089
  • domagrozumab
  • landogrozumab
  • luspatercept
  • OSX-200
  • SRK-015
  • trevogrumab

開發暫停的產品

開發中止的產品

值得注意的最新趨勢、新聞稿 (共15件)

附錄

圖表一覽

目錄
Product Code: GMDHC0052TDB

Summary

Global Markets Direct's, 'Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Pipeline Review, H1 2016', provides in depth analysis on Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted pipeline therapeutics.

The report provides comprehensive information on the Growth/Differentiation Factor 8 (Myostatin or GDF-8), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Growth/Differentiation Factor 8 (Myostatin or GDF-8)
  • The report reviews Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Growth/Differentiation Factor 8 (Myostatin or GDF-8)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Growth/Differentiation Factor 8 (Myostatin or GDF-8) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Growth/Differentiation Factor 8 (Myostatin or GDF-8) Overview
  • Therapeutics Development
    • Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Products under Development by Stage of Development
    • Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Products under Development by Therapy Area
    • Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Products under Development by Indication
  • Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Products under Development by Companies
  • Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Companies Involved in Therapeutics Development
    • Acceleron Pharma, Inc.
    • Atara Biotherapeutics, Inc.
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • Milo Biotechnology LLC
    • Pfizer Inc.
    • Regeneron Pharmaceuticals, Inc.
    • Sarepta Therapeutics, Inc.
    • Scholar Rock, Inc.
  • Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Drug Profiles
    • AAV1-Foliistatin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AAV9-Follistatin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ACE-083 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ACE-2494 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ACE-2798 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ATA-842 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-986089 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • domagrozumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • landogrozumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • luspatercept - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OSX-200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SRK-015 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • trevogrumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Dormant Projects
  • Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Discontinued Products
  • Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Featured News & Press Releases
    • May 19, 2016: Acceleron Announces Data Presentations with Luspatercept at the 21st Congress of the European Hematology Association
    • May 09, 2016: Follistatin Gene Therapy Increases Function in Inclusion Body Myositis Patients
    • Dec 07, 2015: FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Lower-Risk Myelodysplastic Syndromes
    • Dec 05, 2015: Celgene and Acceleron Announce New Results from an Investigational Study with Luspatercept in Myelodysplastic Syndromes Presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition
    • Dec 01, 2015: Acceleron Announces Oral Plenary Presentation for ACE-083 in the Late Breaking Clinical Trials Session at the 8th International Conference on Cachexia, Sarcopenia and Muscle Wasting
    • Nov 05, 2015: Acceleron Announces New Data on Luspatercept at the 2015 American Society of Hematology Annual Meeting
    • Oct 23, 2015: Acceleron Highlights Phase 3 Studies, New Clinical Results and Research Strategies at Research and Development Day Event
    • Oct 01, 2015: Acceleron Presents Preclinical Data for ACE-083 at the 20th International Annual Congress of the World Muscle Society
    • Oct 01, 2015: Acceleron Presents Preclinical Data for ACE-2494 at the 20th International Annual Congress of the World Muscle Society
    • Sep 23, 2015: Scholar Rock Presents First Data for Niche Modulator Inhibiting Myostatin Activation and Announces SRK-015 as Lead Drug Program
    • Jun 12, 2015: Acceleron Announces New Luspatercept Phase 2 Clinical Results at the 20th Congress of the European Hematology Association
    • Jun 09, 2015: Acceleron Pharma to Host Conference Call and Webcast to Review New Luspatercept Data Presented at the 20th Congress of the European Hematology Association
    • May 21, 2015: Acceleron to Present Luspatercept Clinical Trials at the 20th Congress of the European Hematology Association
    • May 18, 2015: FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Beta-Thalassemia
    • May 02, 2015: Luspatercept Data Presented at the 13th International Symposium on Myelodysplastic Syndromes
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Acceleron Pharma, Inc., H1 2016
  • Pipeline by Atara Biotherapeutics, Inc., H1 2016
  • Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Pipeline by Eli Lilly and Company, H1 2016
  • Pipeline by Milo Biotechnology LLC, H1 2016
  • Pipeline by Pfizer Inc., H1 2016
  • Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016
  • Pipeline by Sarepta Therapeutics, Inc., H1 2016
  • Pipeline by Scholar Rock, Inc., H1 2016
  • Dormant Projects, H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top